Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis

被引：0
|
作者：
Moura, Filipe A.
Raz, Itamar
Cahn, Avivit
Goodrich, Erica
Bhatt, Deepak L.
Leiter, Lawrence A.
Wilding, John
Gause-nilsson, Ingrid A.
Mosenzon, Ofri
Sabatine, Marc S.
Wiviott, Stephen D.
机构：
来源：
CIRCULATION | 2021年 / 144卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13182
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Letter by Chen et al Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial"
    Chen, Zhi-Qing
    Chen, Feng
    Li, Lang
    CIRCULATION, 2020, 142 (10) : E127 - E128
  • [32] Effects of Dapagliflozin on Progression of Diabetic Kidney Disease: Analysis from DECLARE-TIMI 58 Trial
    Mosenzon, Ofri
    Wiviott, Stephen D.
    Zelniker, Thomas A.
    Heerspink, Hiddo L.
    Dwyer, Jamie P.
    Cahn, Avivit
    Gause-Nilsson, Ingrid Anna
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    DIABETES, 2019, 68
  • [33] Dapagliflozin vermindert das Risiko für Krankenhausaufenthalte von Typ-2-Diabetes-PatientenNeue Ergebnisse aus der DECLARE-TIMI 58-StudieDapagliflozin reduces the risk for hospitalization in patients with type 2 diabetesNew results from the DECLARE-TIMI 58 trial
    Imke Schamarek
    Die Diabetologie, 2023, 19 (5) : 702 - 704
  • [34] Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial"
    Zelniker, Thomas A.
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2020, 142 (10) : E129 - E130
  • [35] The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial
    McEwan, Phil
    Morgan, Angharad R.
    Boyce, Rebecca
    Bergenheim, Klas
    Gause-Nilsson, Ingrid A. M.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Johansson, Peter A.
    Mosenzon, Ofri
    Cahn, Avivit
    Wilding, John P. H.
    DIABETES OBESITY & METABOLISM, 2021, 23 (04): : 1020 - 1029
  • [36] Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
    Bonaca, Marc P.
    Wiviott, Stephen D.
    Zelniker, Thomas A.
    Mosenzon, Ofri
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Goodrich, Erica L.
    De Mendonca Furtado, Remo Holanda
    Wilding, John P. H.
    Cahn, Avivit
    Gause-Nilsson, Ingrid A. M.
    Johanson, Per
    Fredriksson, Martin
    Johansson, Peter A.
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    CIRCULATION, 2020, 142 (08) : 734 - 747
  • [37] Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
    Moura, F.
    Wiviott, S.
    Chertow, G.
    Dwyer, J.
    Gause-Nilsson, I
    Johansson, P.
    Langkilde, A.
    McMurray, J.
    Mosenzon, O.
    Raz, I
    Rossing, P.
    Wheeler, D.
    Sabatine, M.
    Heerspink, H.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2407 - 2407
  • [38] Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo-Insights from DECLARE-TIMI 58
    Kang, Yu Mi
    Melloni, Giorgio E. M.
    Cahn, Avivit
    Raz, Itamar
    Moura, Filipe
    Bhatt, Deepak L.
    Inzucchi, Silvio E.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John
    Gause-Nilsson, Ingrid A.
    Oscarsson, Jan
    Marston, Nicholas
    Ruff, Christian T.
    Sabatine, Marc S.
    Wiviott, Stephen D.
    DIABETES, 2024, 73
  • [39] Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study
    Norhammar, Anna
    Bodegard, Johan
    Nystrom, Thomas
    Thuresson, Marcus
    Rikner, Klas
    Nathanson, David
    Eriksson, Jan W.
    DIABETES OBESITY & METABOLISM, 2019, 21 (12): : 2651 - 2659
  • [40] Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
    Cahn, Avivit
    Raz, Itamar
    Leiter, Lawrence A.
    Mosenzon, Ofri
    Murphy, Sabina A.
    Goodrich, Erica L.
    Yanuv, Ilan
    Rozenberg, Aliza
    Bhatt, Deepak L.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    DIABETES CARE, 2021, 44 (05) : 1159 - 1167
12345